| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1102 | 2014 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 706 | 2009 |
| Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ... The lancet oncology 11 (9), 845-852, 2010 | 307 | 2010 |
| High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 305 | 2008 |
| FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ... European journal of cancer 50 (1), 57-63, 2014 | 242 | 2014 |
| Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ... Journal of the National Cancer Institute 103 (1), 21-30, 2011 | 232 | 2011 |
| Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ... Annals of Oncology 26 (4), 724-730, 2015 | 191 | 2015 |
| Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results … C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ... Annals of oncology 26 (6), 1188-1194, 2015 | 189 | 2015 |
| First-line chemotherapy for mCRC—a review and evidence-based algorithm C Cremolini, M Schirripa, C Antoniotti, R Moretto, L Salvatore, G Masi, ... Nature reviews Clinical oncology 12 (10), 607-619, 2015 | 180 | 2015 |
| Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer M Schirripa, C Cremolini, F Loupakis, M Morvillo, F Bergamo, F Zoratto, ... International journal of cancer 136 (1), 83-90, 2015 | 171 | 2015 |
| Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study D Santini, M Tampellini, B Vincenzi, T Ibrahim, C Ortega, V Virzi, ... Annals of oncology 23 (8), 2072-2077, 2012 | 154 | 2012 |
| Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic … R Moretto, C Cremolini, D Rossini, F Pietrantonio, F Battaglin, A Mennitto, ... The oncologist 21 (8), 988-994, 2016 | 138 | 2016 |
| Genetic modulation of the let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ... The pharmacogenomics journal 10 (5), 458-464, 2010 | 133 | 2010 |
| FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial … A Falcone, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... Journal of Clinical Oncology 31 (15_suppl), 3505-3505, 2013 | 119 | 2013 |
| FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the … L Fornaro, S Lonardi, G Masi, F Loupakis, F Bergamo, L Salvatore, ... Annals of oncology 24 (8), 2062-2067, 2013 | 114 | 2013 |
| Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a … C Cremolini, C Antoniotti, S Lonardi, G Aprile, F Bergamo, G Masi, ... JAMA oncology 4 (4), 529-536, 2018 | 113 | 2018 |
| Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ... British journal of cancer 104 (8), 1262-1269, 2011 | 108 | 2011 |
| Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer V Catalano, F Loupakis, F Graziano, R Bisonni, U Torresi, B Vincenzi, ... Annals of oncology 23 (1), 135-141, 2012 | 101 | 2012 |
| Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label … C Antoniotti, D Rossini, F Pietrantonio, A Catteau, L Salvatore, S Lonardi, ... The Lancet Oncology 23 (7), 876-887, 2022 | 94 | 2022 |
| Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer M Manzoni, B Rovati, M Ronzoni, F Loupakis, S Mariucci, V Ricci, ... Oncology 79 (3-4), 187-196, 2011 | 92 | 2011 |
